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Purpose In the United Kingdom Collaborative Trial of Ovarian Cancer 
Screening(UKCTOCS) women in the multimodal (MMS) arm had a serum CA125 test (first-
line), with those at increased risk, having repeat CA125/ultrasound (second-line test). 
CA125 was interpreted using the ‘Risk of Ovarian Cancer Algorithm’(ROCA). We report on 
performance of other serial algorithms and a single CA125 threshold as a first line screen in 
the UKCTOCS dataset. 
Experimental Design 50,083 post-menopausal women who attended 346,806 MMS 
screens were randomly split into training and validation sets, following stratification into 
cases (ovarian/tubal/peritoneal cancers) and controls. The two longitudinal algorithms, a 
new serial algorithm, method of mean trends (MMT) and the parametric empirical Bayes 
(PEB) were tested run in the blinded validation set and the performance characteristics, 
including that of a single CA125 threshold, were compared.  
Results The area under receiver operator curve (AUC) was significantly higher (p=0.01) for 
MMT (0.921) compared to CA125 single threshold (0.884). At a specificity of 89.5%, 
sensitivities for MMT (86.5%; 95%CI:78.4-91.9) and PEB (88.5%; 95%CI: 80.6-93.4) were 
similar to that reported for ROCA (sensitivity 87.1%; specificity 87.6%; AUC 0.915) and 
significantly higher than the single CA125 threshold (73.1%; 95%CI: 63.6-80.8).  
Conclusions These findings from the largest available serial CA125 data set in the general 
population provide definitive evidence that longitudinal algorithms are significantly superior to 
simple cut-offs for ovarian cancer screening. Use of these newer algorithms requires 
incorporation into a multimodal strategy. The results highlight the importance of incorporating 





Earlier diagnosis of ovarian cancer remains a key need as it continues to be the leading 
cause of death from gynecological cancer, accounting for 5% of all female cancer deaths. In 
the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) 
multimodal screening incorporating a longitudinal CA125 algorithm (ROCA) outperformed 
threshold rules and resulted in significant detection of earlier stage disease but no definitive 
mortality reduction compared to no screening. We now show that other longitudinal CA125 
algorithms, a newly developed, Method of Mean Trends (MMT), and the published 
Parametric Empirical Bayes (PEB) algorithm have comparable performance as a first line 
annual test and also significantly outperform simple cut-offs. The advantages of these new 
algorithms are computational simplicity with incorporation of additional biomarkers much 
easier. These findings highlight the need to incorporate serial change in biomarker levels for 
screening/early detection of cancer. While ovarian cancer screening is not recommended in 
the general population, our findings have immediate implications for high-risk women in 
countries where twice a year CA125 screening is an option. It highlights the importance to 
look at trends and not absolute cut-offs alone. Use of the new algorithms requires 






Ovarian cancer remains the leading cause of death from gynecological cancer among 
women and accounts for 5% of all female deaths from cancer, corresponding to annual 
deaths of around 4,100 in the UK (1), 42,700 in Europe, 22,280 in USA (2) and 152,000 
worldwide (1). Most women are diagnosed in advanced stage (Stage III-IV) with reported 5-
year survival rates of 19% (Stage III) and 3% (Stage IV) respectively. The higher survival 
rates of 70-90% in earlier stage (Stage I-II) disease has driven international screening 
efforts to detect the disease earlier (3). To date the large screening trials have used 
measurement of a tumour marker CA125 (Cancer Antigen 125 protein) in the blood and 
transvaginal ultrasound to image the ovaries. 
 
In the ovarian component of the Prostate Lung Colorectal and Ovarian Cancer Screening 
Trial (PLCO), an absolute CA125 cut-off of 35 U/mL and pelvic ultrasound was used as first 
line annual tests. There was no stage shift or reduction in ovarian cancer deaths between 
the screen and no screening (control) arms (4). More recently in UKCTOCS, multimodal 
screening (MMS) resulted in significant detection of earlier stage disease in women with 
invasive epithelial ovarian/tubal/peritoneal cancers (iEOC/PPC) compared to the control 
arm. In a pre-specified subgroup of the primary mortality analysis ROCA reduced mortality 
in the 80% of cancers where a baseline CA125 was measured, that is, in incident cancers. 
However further follow-up is needed to assess whether screening results in a definitive 
mortality reduction for all ovarian cancers (5). In MMS the annual first-line test was CA125 
which was interpreted using the longitudinal Risk of Ovarian Cancer Algorithm (ROCA). 
Women found to be at increased risk had repeat CA125 and/or transvaginal ultrasound 
(second-line test).  
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As a first line test, ROCA had significantly better performance characteristics for detection of 
invasive epithelial ovarian/tubal cancer (iEOC/PPC) compared to a CA125 cut-off in the 
UKCTOCS dataset. Only 48% of the incident cases would have been detected at the last 
annual incidence screen if a CA125 cut-off of 35 U/mL had been used (6). The statistical 
model underlying the ROCA is built on two important assumptions: (i) each woman has her 
own baseline CA125 level and variation about this level, and (ii) after cancer inception the 
tumor sheds CA125 into the circulation whereupon serum CA125 increases exponentially 
reflecting tumor doubling. ROCA best detects cancers where a significant increase above a 
woman’s CA125 baseline occurs; hence the pre-specified subgroup analysis for cancers 
where a CA125 baseline was measured during screening. The second assumption 
corresponds to a change point in the serum CA125 time series as the cancer develops (7-
9). The development of new ovarian cancer detection algorithms that further minimize 
assumptions remains an important scientific goal as does the performance of serial 
algorithms compared to single thresholds in the context of screening. Parametric empirical 
Bayes (PEB) (10) is another algorithm that has been described for interpreting serial CA125 
data. 
 
In this paper we use the data from 50,083 post-menopausal women who underwent 
346,806 annual screens and follow-up in the multimodal (MMS) arm during the course of 
UKCTOCS to (1) build a new algorithm for longitudinal analysis of cancer biomarkers, 
“method of mean trends” (MMT), which measures the dynamics of the biomarker over time 
using multiple trend indices and (2) investigate the performance of both longitudinal 




Patients and methods 
 
In UKCTOCS, 202,638 low-risk postmenopausal women aged 50-74 were randomized 
between 2001 and 2005 to one of two screening (ultrasound: USS; multimodal: MMS) or a 
no screening (control: C) arm in a ratio of 1:1:2. Exclusion criteria were self-reported 
previous bilateral oophorectomy or ovarian malignancy, increased risk of familial ovarian 
cancer, or active non-ovarian malignancy. The trial was approved by the United Kingdom 
North West Multicentre Research Ethics Committee (ISRCTN22488978) and listed on 
ClinicalTrials.gov (NCT00058032). Trial design, including details of recruitment and 
randomization have been described elsewhere (5, 6, 11). All women provided written 
informed consent. 
 
Women were offered annual screening from randomization to 31st December 2011. The 
screening protocol and management of screen-detected abnormalities have been previously 
described (6, 11). In brief, in the MMS group women had an annual serum CA125 which 
was interpreted using ROCA. If the ‘risk of ovarian cancer’ was normal they were triaged to 
annual screening; if intermediate they had repeat CA125 in three months and if elevated, 
they had repeat CA125 and transvaginal scan.  
 
All volunteers were followed using their National Health Service number through data 
linkage with the appropriate national agencies for cancer registrations and/or deaths as well 
as by postal questionnaires. Primary cancer site, morphology, stage and grade were 
assigned as of 31st December 2014 following review of all medical notes by an independent 
outcomes review committee (two pathologists and two gynecological oncologists) who were 
blinded to the randomization group as previously described (5, 6, 11).  
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Sample set for current analysis 
The sample set is derived from data on all eligible women randomized to the MMS arm who 
were included in the mortality analysis and had a CA125 measurement (5). ‘Cases’ were 
women confirmed at censorship (31st December 2014) by the outcomes review committee 
to have iEOC/PPC, borderline epithelial and non-epithelial ovarian cancer. Controls were all 
women who did not have ovarian/tubal/peritoneal cancer. The dataset of eligible women 
was randomly divided in a stratified manner, so that both controls and cases were each split 
in a 1:1 ratio into a training and validation set.  
 
Since the ROCA was prospectively evaluated in UKCTOCS, following the annual screen, all 
repeat CA125 tests were triggered by ROCA. Hence to limit concerns over potential bias, 
the CA125 data for this analysis was limited to annual measurements. All CA125 values 
were transformed by taking a logarithm of their values prior to applying the algorithms since 
on this scale the distribution was much closer to a Normal distribution than the original 
scale.  
 
Development/training of algorithm  
 
Method of Mean Trends (MMT) algorithm: This new method evaluates the dynamics of 
longitudinal markers by averaging weighted derivatives of marker changes for all intervals of 
time between measurements. Since the most recent biomarker measurement is more 
important than all previous ones, weights were proposed in order to take into account the 
importance of those samples, which were closer to the most recent observation. For each 
individual woman “𝑖” the whole serial pattern, 𝑌𝑖,𝑗 , 𝑗 = 1. . 𝑇, was mapped into a new five-
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variable space including its mean derivative, the three indices described below and the most 
recent measurement 𝑌𝑖,𝑇. In this way, instead of the initial collection of 𝑇 measurements over 
time for a particular marker, the dimension to 5  variables for the CA125 marker was 
reduced. For this marker, and each interval between two consecutive measurements, the 
derivative was approximated using the expression ∆𝑌𝑖𝑗/∆𝑡𝑖𝑗 , where ∆𝑌𝑖,𝑗 = 𝑌𝑖,𝑗+1 − 𝑌𝑖,𝑗 , 
∆𝑡𝑖,𝑗 = 𝑡𝑖,𝑗+1 − 𝑡𝑖,𝑗 , then the mean derivative was calculated, giving the most recent 




𝑗=1  , where the weights 𝑤𝑖𝑗  were computed for each 
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where 𝑡𝑖,𝑇 was the age of the patient at the time of the most recent sample while 𝑡𝑖,𝑗 was the 
age of the patient when the 𝑗-th sample was taken. In this way, more recent measurements 
were provided a higher weighting. Apart from the mean derivative, multiple indices were 
analyzed, and after using Akaike Information Criterion (AIC) for the model selection, which 
deals with the trade-off between the goodness of fit of the model and the simplicity of the 
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As a final step, MMT used a logistic regression model based on the weighted average 
derivatives, the described indices 1 to 3, and the latest currently available measurement 
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taken for each patient. This logistic regression model (12) was then fitted to obtain 
coefficients, which provide predictions on the probability scale which were the basis of the 
rule for classification into cases and controls. If there was only a single CA125 value, the 
threshold at 90% specificity was used for classification. An important advantage of this 
proposed approach is the ability to use more than one marker simultaneously by adding into 
the logistic regression model-average derivatives and other indices calculated separately for 
each of marker 𝑚 = 1. . 𝑀. 
In summary, the MMT algorithm applied for the prediction of disease based on serial 
measurements is as follows: 
- Step 1: approximate the time-derivatives of the biomarker series, for each patient and 
each  measurement, as ∆𝑌𝑖𝑗/∆𝑡𝑖𝑗 
- Step 2: calculate the weight for each derivative as 𝑤𝑖𝑗 =
1
𝑡𝑖,𝑇−(𝑡𝑖,𝑗+1+𝑡𝑖,𝑗)/2
   





- Step 4: calculate the indices Ai, Bi, Ci in expressions (1), (2) and (3) 
- Step 5: use AIC to select the predictors (out of weighted derivative, indices Ai, Bi, Ci 
and raw measurement of the biomarker) that best explains the labels of the patients 
(control=0, case=1) 
- Step 6: fit the logistic regression with the selected predictors and the labels of all 
patients.  
 
Once the logistic regression is fitted it can be used to predict the risk of the disease for the 
new patient. If more than 1 biomarker measurement is available for all the patients, the 
procedure above is repeated calculating the 5 predictors for each biomarker (Step 1-4) and 
including them all in the AIC variable selection step (Step 5). 
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Parametric Empirical Bayes (PEB) algorithm: This method, described previously (10), 
allows calculation of a biomarker threshold for each subject based on their previous 
screening history. The approach requires a serial pattern of markers in healthy women and 
can be used for analysing the performance of new individual markers. Suppose a subject 
with 𝑛 historical screens with an average marker concentration 𝑦𝑛̅̅ ̅ is going to have a new 
screen and assuming that we operate at level 𝛼, the threshold given by the PEB algorithm 
is: 
 
𝑇 = 𝜇 + (𝑦𝑛̅̅ ̅ − 𝜇)𝐵𝑛 + 𝑧𝛼√1 − 𝐵1𝐵𝑛√𝑉, 
 
where 𝜇 is the population mean, 𝐵𝑛 =
𝜏2
𝜎2/𝑛+𝜏2
; 𝑉 = 𝑉𝑎𝑟[𝑌𝑖,𝑗] is the variance of measurements 
𝑌𝑖,𝑗 ; 𝜎





2 = 𝑉 − 𝜎2 ; 𝑧𝛼  is the 𝛼 -quantile of a standard normal distribution (𝑧𝛼 = 1.96  when 
𝛼 = 0.975). At the initial screen 𝐵0 = 0 and so the threshold becomes: 
𝑇 = 𝜇 + 𝑧𝛼√𝑉. 
It should be noted here that, since after obtaining all the parameters including the level 𝛼 
from the training set for each patient the PEB algorithm yields an outcome of 0 (no cancer) 
or 1 (cancer present), depending on whether the last measurement is higher than the 
threshold or not, we consider only the value of the sensitivity at a fixed level of specificity in 
the sequel. The area under the ROC curve cannot be used to analyse performance of the 
PEB algorithm because in this setting the outcome (0 or 1) does not allow the use of 




OB was provided all data including CA125 measurements for each woman, dates of birth, 
dates when the measurements were taken, case-control status and dates of diagnosis for 
cancer cases on the training set. The MMT and PEB were developed/trained respectively 
using the training set by OB. The annual CA125 values were used in a sequential manner. 
At each annual screen, all previous annual measurements were incorporated and a new 
PEB/MMT classification was determined. The outcome for the PEB was either 0 or 1 for 
each measurement in a longitudinal time series while that for MMT was continuous results 
of the logistic regression. At the training stage a threshold was calculated for the MMT to 
provide similar specificity to annual ROCA classification of ‘normal risk’ which was 87.6% in 
UKCTOCS6. Since MMT uses trend indices, which cannot be calculated for the first annual 
measurement (no previous history), the 0.9 quantile was calculated from the control 
measurements. After that, for every patient, the first annual measurement was compared to 
this quantile and depending on whether the measurement was higher or not, risk was 




The validation set comprised of a set of women with their serial annual CA125 
measurements but no outcomes. OB as described above, normalized all measurements by 
taking a logarithm of their values. The annual CA125 values were used in a sequential 
manner. At each annual screen, all previous annual measurements were incorporated and a 
PEB and MMT classification (and prediction probability) was calculated. The data was then 
transferred to MB who unblinded the outcome data and compared the performance of the 




The primary outcome was iEOC/PPC diagnosed within 1 year of annual CA125 
measurement. Women with borderline epithelial or non-epithelial ovarian cancer were 
excluded from this analysis. Secondary outcome was all primary ovarian/tubal/peritoneal 
cancers and the whole data set was used for this analysis. When dealing with the 
determination of outcomes, the last blood sample was considered as a true positive (if 
within 1 year from diagnosis) and all prior annual samples as true negatives. A subgroup 
analysis was undertaken which was restricted to cancers diagnosed between 1-2 years 
from last measurement in order to see if there was any difference in lead time between the 
algorithms. For this analysis, if there was more than one measurement within 1-2 years then 
the closest to 2 years was used as the ‘last measurement’. As above the last measurement 
was considered as true positive and prior annual samples considered true negatives. All 
annual samples beyond the last measurement were discarded. When dealing with controls, 
all samples were included as true negatives.  
 
The performance characteristics of the two algorithms and CA125 were evaluated and 
compared in terms of 1) the sensitivity (proportion detected of those with cancer) at a fixed 
specificity (proportion of controls correctly detected not to have cancer): for PEB the 
threshold was implicit in its formulation; for MMT the threshold was the value which provided 
0.9 specificity in the training set; for CA125 the threshold was the common value of >30 
U/ml for postmenopausal women and 2) the area under the Receiver Operating 
Characteristic (ROC) curve (AUC). Inference for the ROC curves was based on cluster-
robust standard errors that accounted for the serially correlated nature of the samples. It 




The eligible women comprised all 50,083 of the 50,624 randomised to the MMS group who 
attended for screening and had an annual serum CA125 level measured. They underwent 
347,002 annual screens (median 8, IQR 6-9). Median follow-up was 11.1 years (IQR 10.0–
12.0).(5)  
 
During follow-up, 332 developed ovarian/tubal/peritoneal cancer as of 31st December 2014. 
The training set comprised of 25,041 women with 161(139 iEOC/PPC) cases and the 
validation set 25,042 women with 171(143 iEOC/PPC) cases (Table 1). Baseline 
characteristics of women included in the training and validation sets were balanced (Table 
2). Morphology of cases together with histological subtype and stage of iEOC/PPC are 
presented in Table 3. Longitudinal algorithms were applied to the validation set, which 
contained 174,270 annual CA125 measurements from 25,042 women (Table 1).  
 




Primary analysis - 
cancer diagnosed <1 
year of sample 
Secondary analysis - 
cancer diagnosed >1 

















Primary outcome - Invasive epithelial ovarian/tubal/peritoneal cancer 
Training set 
Cases 139 621 91 375 
  
Controls 24880 172039 24880 172039 
Validation set     
Cases 143 666 104 466 90 383 
Controls 24871 173478 24871 173478 24871 173478 
Secondary outcome  - Ovarian*/tubal/peritoneal cancers 
Training set 
Cases 161 693 108 433   
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Controls 24880 172039 24880 172039 
Validation set 
Cases  171 792 123 553 109 468 
Controls 24871 173478 24871 173478 24871 173478 
Abbreviations: CA125, cancer antigen 125 
* includes borderline, non-epithelial and invasive epithelial 
 
 
Table 2: Baseline characteristics of cases and controls in training and validation sets 
 
Baseline characteristics  Training set Validation set 
No of women 25041 25042 
Median age at recruitment (years) 60.60 60.68 
BMI 25.7 25.72 
OCP use 59.5% 59.3% 
Duration of OCP use (years) 5 5 
Hysterectomy 19.4% 19.0% 
% White ethnicity 97.0% 97.0% 
HRT use 18.7% 18.7% 
Personal history of breast cancer 3.7% 3.7% 
Abbreviations: BMI, body mass index; OCP, oral contraceptive pill; HRT, hormone replacement 
therapy 
 
















Morphology of cases 
    
Non-epithelial ovarian cancer 3 5 3 4 
Borderline epithelial ovarian cancer 19 23 16 15 
Invasive epithelial ovarian/tubal 
cancer 
135 131 79 93 
Primary peritoneal cancer 4 12 11 11 
Total 161 171 109 123 
Histological type of invasive 
epithelial ovarian/tubal/peritoneal 
cancer  
    
Type I 21 23 13 17 
Endometrioid (low grade) 9 6 3 5 
Serous (low grade) 6 5 2 5 
Clear cell 5 9 8 6 
Mucinous 1 3 0 1 
Type II 103 113 74 84 
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High grade serous 81 90 62 68 
Carcinoma, NOS 14 8 4 4 
Endometrioid (high grade) 6 10 6 9 
Carcinosarcoma 2 5 2 3 
Type uncertain 15 7 3 3 
Carcinoma, NOS 10 6 3 3 
Serous (grade unknown) 4 1 0 0 
Small cell carcinoma 1 0 0 0 
Total 139 143 90 104 
Stage of invasive epithelial 
ovarian/tubal/peritoneal cancer      
I 36 33 19 24 
II 11 20 16 17 
III 74 76 47 57 
IV 18 13 8 6 
Total 139 142* 90 104 
Abbreviations: NOS, not otherwise specified 
*Unable to stage one case in Validation Set 
** One woman diagnosed with small cell carcinoma in the training set 
 
Figure 1 shows the ROC curves for MMT and the CA125 threshold rules for detection of 
iEOC/PPC cases diagnosed within 1 year of last annual sample (primary analysis). MMT 
provided a higher area under the curve, 0.921 compared with 0.884 for the single threshold 
rule. The AUC for CA125 single threshold was significantly lower than MMT (p=0.01).  
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Figure 1 Performance characteristics of of CA125 interpretted using MMT, threshold rules, 
PEB and ROCA for detection of iEOC/PPC cases. Circle points give particular values of 
sensitivity and specificity provided by MMT and PEB corresponding to cut-offs obtained 
from the training set (MMT and PEB), CA125 using 22 and 30 U/ml cut-offs and ROCA as 
reported in (6) . 
Abbreviations: PEB, parametric empirical Bayes; MMT, method of mean trends; CA125, 
cancer antigen 125; AUC, area under roc-curve 
 
At a specificity of 89.5% for PEB (for which it was not possible to compute AUC), 
sensitivities were 73.1% (95%CI: 63.6-80.8) for the single CA125 threshold, 86.5% (95%CI: 
78.4-91.9) for MMT and 88.5% (95%CI: 80.6-93.4) for PEB. In a hypothetical cohort of 
100,000 women with an average incidence of about 50 per 100,000 a year this result would 
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imply that MMT would detect about (86.5-71.3)*50/100≈7 extra cases and PEB would detect 
about (88.5-71.3)*50/100≈8 extra cases compared to the CA125 cut-off. To assess the 
significance of differences in sensitivity at fixed specificity for different algorithms, 
McNemar’s exact test was used. The sensitivity was significantly different compared to the 
single threshold rule. The longitudinal approaches were not significantly different from each 
other. 11.5% (12/104) of iEOC/PPC were not detected on the last annual screen by either 
longitudinal algorithm.  
 
Table 4 shows the sensitivity, specificity and AUC confidence intervals for each of the 
algorithms and the CA125 single threshold rule in the primary and secondary analyses for 
the primary and secondary outcomes for both sets. Both longitudinal algorithms provided 
similar characteristics for both outcomes in the primary and secondary analyses. In all the 
subgroups of the analysis, PEB and MMT provided higher sensitivity compared with the 
single CA125 threshold.  
 
Table 4: Cut-point sensitivity and specificity and area under curve (AUC) for primary 
and secondary analyses  
 
  
Primary analysis – cancer diagnosed 
<1 year after sample 
Secondary analysis - cancer 
diagnosed 1-2 years after sample 
PEB MMT** 
CA125 cut-
off >30 U/ml 
PEB MMT** 
CA125 cut-
off >30 U/ml 
Primary outcome - Invasive epithelial ovarian/tubal/peritoneal cancer   
Training set   
Sensitivity  




































































Secondary outcome  - All Ovarian*/tubal/peritoneal cancers   
Training set   
Sensitivity  



































































Abbreviations: PEB, parametric empirical Bayes; MMT, method of mean trends; CA125, cancer 
antigen 125; AUC, area under roc-curve; CI, confidence interval 
* includes borderline, non-epithelial and invasive epithelial 
** MMT considered abnormal if >1/2570 
 
The performance for non-epithelial and borderline cancer diagnosed within 1 year of last 
annual sample is detailed in Supplementary Table 1. Both algorithms performed similarly.  
 
Figure 2 shows the ROC curves for iEOC/PPC diagnosed >1 and <2 years from last annual 
sample (secondary analysis). Here MMT (0.613) had slightly higher AUC compared to the 
CA125 (0.598), although the difference was not significant (p=0.639). 
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Figure 2 Secondary analysis ROC curves for CA125 interpreted using MMT and threshold 
rules for detection of iEOC/PPC cases. Circle points on the ROC curves give particular 
values of sensitivity and specificity provided by MMT and PEB corresponding to cut-offs 
obtained from the training set (MMT and PEB). 
Abbreviations: PEB, parametric empirical Bayes; MMT, method of mean trends; CA125, 




In the largest available serial data set of CA125 results in the general population comprising 
347,002 serial annual CA125 measurements from 50,083 women who participated in 
multimodal screening in UKCTOCS with no selection bias, two serial biomarker algorithms 
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had high and comparable performance in the context of a first line screening test for 
invasive epithelial ovarian/tubal/peritoneal cancer and were significantly superior to a 
CA125 cut-off. We have previously reported that the longitudinal algorithm ROCA 
outperforms CA125 cut-offs (6). We now show that in comparison to thresholds, other 
longitudinal algorithms have similar superior performance as a first line test as ROCA 
(sensitivity 87.1%; specificity 87.6%; AUC 0.915) in UKCTOCS (6). The results emphasize 
the need to incorporate serial change in biomarker levels in the context of screening and 
early detection of cancer. Screening is not recommended in the general (low-average risk) 
population as there is no definitive evidence of a mortality benefit (13). However, our 
findings have immediate implications for high-risk women in countries where CA125 
screening is an option (14). The results clearly show that longitudinal approaches are better 
tools for the early detection of invasive epithelial ovarian cancer than a single threshold rule 
which is the current norm.  
 
We compared two serial algorithms, PEB(10) the only other reported serial algorithm that 
has been used for ovarian cancer screening and our newly developed algorithm (MMT) as a 
first line test for ovarian cancer screening. The MMT evaluates the dynamics of longitudinal 
markers by analyzing different trend indices while the PEB models marker trajectory in 
healthy individuals over time to generate person-specific positivity thresholds. We 
developed the MMT algorithm and trained it together with the PEB in a random training set 
which included half the women and half the ovarian/tubal/PPC cancers that were diagnosed 
prior to 31st Dec 2014 in the MMS arm of UKCTOCS. The ROCA, which is built on a 
change-point pattern in an individual’s CA125 values, was developed on data from previous 
trials and was prospectively evaluated in UKCTOCS. In future, it will be further refined using 
the data from the UKCTOCS training set and the refined ROCA will be compared to MMT, 
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PEB performance in the validation test. The advantages of the MMT and PEB algorithms 
are that they are computationally simpler than ROCA and therefore can be more easily 
applied to longitudinal analysis of multiple biomarkers. The MMT algorithm is based on the 
construction of a logistic regression and therefore for any additional biomarker we only have 
to calculate trend indices, add them to the logistic regression model and fit it. An advantage 
of ROCA is that it incorporates tumor doubling into the model, a well-accepted biological 
dynamic in cancer biology, and is therefore potentially more powerful than algorithms that 
do not incorporate such biology. 
 
Our results confirm the superiority of serial algorithms for detection of iEOC/PPC diagnosed 
within one year of the last annual screen. Previous retrospective analysis has involved small 
sample sets. Drescher et al evaluated PEB in a serial serum CA125 sample set from 44 
incident ovarian cancer cases identified from participants in the PLCO (Prostate Lung 
Colorectal and Ovarian) Cancer Screening Trial Comparison(15). Application of these new 
algorithms require incorporation into a multimodal strategy with development of cut-offs so 
that women can be triaged to repeat CA125 testing and second line tests such as 
transvaginal ultrasound (11) or other novel tests such as circulating tumour DNA (ctDNA) 
(16). The latter are essential to increase the specificity of the screening strategy and 
decrease the number of women referred to surgery.  
 
In our secondary analysis where we determined sensitivity of the serial algorithms for 
detection of cases diagnosed more than one year but within 2 years after the annual 
sample, both MMT and PEB detected similar small proportions of cases but it is likely that 
this would not have led to improved lead time. This suggests that further improvements in 
sensitivity require inclusion of additional ovarian cancer biomarkers to confirm the CA125 
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trend detected by the serial algorithms. A highly specific marker such as ctDNA would be 
ideal, but less specific markers such as HE4 may also contribute to earlier diagnosis. We 
are evaluating the HE4 in this sample set and will report in the near future.  
 
Key strengths of our analysis are the size of the dataset, use of the entire cohort with 
minimal selection bias, completeness of data on cancers diagnosed in the cohort ensured 
by linkage to national cancer/death registries using a unique identifier together with two 
rounds of postal follow-up and independent blinded outcome review of iEOC/PPC. The test 
results in the validation set were generated by OB who was blinded to outcomes with the 
unblinding and statistical analysis done independently by MB. The main limitation is that we 
are only able to assess the algorithms as first line tests. Hence it is not possible to assess 
the true performance characteristics when incorporated into a multimodal strategy.  
 
In conclusion, our analysis provides definitive evidence of the superiority of longitudinal 
algorithms compared to single-threshold rules which is the current norm for interpretation of 
serum CA125 as a first line test in ovarian screening. It is likely that this also applies to other 
serum markers used in cancer screening. Use of these newer algorithms in ovarian cancer 
screening requires incorporation into a multimodal strategy and evaluation in clinical trials to 
assess overall performance. 
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